Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

7.2K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Ovarian Cycle01:27

Ovarian Cycle

4.7K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.7K
Oogenesis02:07

Oogenesis

70.6K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
70.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deconstructing triglyceride glucose-body mass index in normal-weight women with polyendocrine metabolic ovarian syndrome.

Fertility and sterility·2026
Same author

The Endocrinological Basis for Polycystic Ovary Syndrome: An Evolutionary Perspective.

Endocrinology·2025
Same author

Origins of polycystic ovary syndrome.

Reproduction (Cambridge, England)·2025
Same author

On the Intimate Relationship of Adiposity to Polycystic Ovary Syndrome.

The Journal of clinical endocrinology and metabolism·2025
Same author

POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome.

Reproduction (Cambridge, England)·2025
Same author

Interface between reproductive and metabolic dysfunction in polycystic ovary syndrome.

Current opinion in obstetrics & gynecology·2025

Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

1.9K

Monoclonal antibody therapy for PCOS?

David H Abbott1, Daniel A Dumesic2

  • 1Department of Obstetrics and Gynecology, University of Wisconsin, Madison, WI 53706, USA; Wisconsin National Primate Research Center, 1223 Capitol Court, Madison, WI 53715, USA.

Cell Metabolism
|June 4, 2025
PubMed
Summary

Researchers developed a novel neutralizing antibody therapy to target polycystic ovary syndrome (PCOS) in infancy. This early intervention in a mouse model successfully eradicated PCOS symptomology, offering a potential new treatment avenue.

More Related Videos

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

12.0K
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

3.5K

Related Experiment Videos

Last Updated: Mar 2, 2026

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

1.9K
A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

12.0K
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

3.5K

Area of Science:

  • Reproductive endocrinology and immunology
  • Developmental biology
  • Animal models of human disease

Background:

  • Polycystic ovary syndrome (PCOS) is a complex endocrine disorder with no current cure, necessitating management of its diverse symptoms.
  • PCOS manifests early, with signs detectable even during infancy.
  • Existing treatments focus on symptom management rather than disease eradication.

Purpose of the Study:

  • To investigate the efficacy of early-stage neutralizing antibody therapy for PCOS.
  • To determine if PCOS can be eradicated by targeting early developmental pathways.
  • To establish a preclinical model for evaluating novel PCOS interventions.

Main Methods:

  • Development and administration of a neutralizing antibody therapy targeting key PCOS pathways.
  • Application of the therapy during the infantile period in a female mouse model.
  • Comprehensive assessment of reproductive, cardiometabolic, and psychological symptomology post-therapy.

Main Results:

  • Infantile administration of neutralizing antibody therapy led to the complete eradication of PCOS symptomology in the mouse model.
  • Early intervention prevented the development of characteristic PCOS phenotypes.
  • The therapy demonstrated a high efficacy in preventing long-term disease manifestation.

Conclusions:

  • Neutralizing antibody therapy administered during infancy presents a potential curative strategy for PCOS.
  • Early intervention is critical for preventing the development and progression of PCOS.
  • This preclinical study provides a foundation for developing infant-targeted therapies for PCOS.